The treatment of metastatic castration-resistant prostate cancer (mCRPC) involves a combination of therapies, including chemotherapy, hormone therapy, immunotherapy, and different medications that ...

Akeega, an oral dual mechanism therapy pairing niraparib with abiraterone, has won a positive committee opinion in Europe for ...

Patients with detectable ctDNA before treatment had a shorter duration of clinical benefit and shorter overall survival. Having detectable circulating tumor DNA (ctDNA) before treatment is associated ...

Enzalutamide may offer a survival advantage compared with abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC), according to 2 US studies of older men. Overall survival ...

PRESS RELEASEAB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE ...

ONCT-534 showed a well-tolerated safety profile in mCRPC patients on a twice-daily dosing schedule, with no grade 3 or higher toxicities reported. Despite trial discontinuation, ONCT-534 demonstrated ...

The term metastatic castration-resistant prostate cancer (mCRPC) refers to a cancer that has spread (metastasized) beyond your prostate gland and for which hormone therapy is no longer effective in ...

Janux Therapeutics' JANX007 shows promising Phase 1 data in treating advanced prostate cancer, with significant PSA level reductions. Early data suggest JANX007 could meet unmet needs in mCRPC ...

(RTTNews) - Pfizer (PFE), on Thursday announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA or talazoparib in combination with XTANDI or enzalutamide for the treatment of metastatic ...

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like wandering through a foggy wilderness, quiet and cautious, afraid that any ...

Clinical and pathologic characteristics of mCRPC were largely similar between younger and older patients. Overall survival was not significantly different between younger and older patients with mCRPC ...

JongSoo Lee, Ph.D., Mathematics & Statistics, Kennedy College of Sciences, University of Massachusetts Lowell Camilla Pimentel, Ph.D., Public Health, Zuckerberg ...